Head to Head Comparison: Zymeworks (NASDAQ:ZYME) and CannTrust (OTCMKTS:CNTTF)

Zymeworks (NASDAQ:ZYME) and CannTrust (OTCMKTS:CNTTF) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility & Risk

Zymeworks has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, CannTrust has a beta of 4.52, indicating that its stock price is 352% more volatile than the S&P 500.

Institutional & Insider Ownership

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 0.1% of CannTrust shares are held by institutional investors. 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Zymeworks and CannTrust”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96 million	16.61	-$81.13 million	($1.37)	-17.59
CannTrust	$15.96 million	0.00	$7.39 million	$0.07	N/A

CannTrust has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than CannTrust, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zymeworks and CannTrust’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
CannTrust	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Zymeworks and CannTrust, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1	1	8	1	2.82
CannTrust	0	0	0	0	0.00

Zymeworks currently has a consensus price target of $36.67, suggesting a potential upside of 52.14%. Given Zymeworks’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Zymeworks is more favorable than CannTrust.

About Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

About CannTrust

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.